シルデナフィルシトラート (バイアグラ) と窒素を併用したシルデナフィルの心臓への影響

F Ishikura¹, S Beppu, T Hamada

¹School of Allied Health Sciences, Osaka University, Faculty of Medicine, Osaka, Japan.

Circulation

|November 15, 2000

まとめ

シルデナフィルチラート (バイアグラ) は正常な冠動脈を広げますが,特に静脈狭窄の血管では,窒素と併用すると,血圧と冠動脈血流の危険な低下を引き起こす可能性があります.

科学分野:

心血管薬理学について
ファルマコダイナミクスは,
ヘモダイナミクス (血動力学)

背景:

シルデナフィルチラート (バイアグラ) は勃起不全の治療に使用されます.
ニトログリセリンと併用すると,著しい低血圧が発生する.
シルデナフィル・シトラートとナイトレートの冠動脈動力学に対する相互作用は,調査を必要とする.

研究の目的:

冠動脈の血流に対するシルデナフィル・シトラートの影響を調査するために.
シルデナフィル・シトラートとニトラートの総合的な効果を,全身血圧と冠動脈の血液動力学に評価する.

主な方法:

ヘモダイナミックパラメータ (全身血圧,肺動脈血圧,冠動脈血流) は,健康なオスビーグルで測定されました.
シルデナフィル・シトラートが投与され,その後,冠動脈の血流の評価が行われました.
イソソorbide dinitrateの急性効果は,シルデナフィルシトラート投与前と後に研究されました.

主要な成果:

シルデナフィル・シトラートは,左側前側下降冠動脈の血流を増加させた.
システミック血圧,肺動脈圧,または円周動脈の流れにおいて有意な変化は観察されなかった.
窒素酸塩とシルデナフィルシトラートの併用投与は,全身血圧と冠動脈静脈静脈静脈静脈静脈静脈静脈静脈静脈静脈静脈静脈静脈静脈静脈静脈静脈静脈静脈静脈静脈静脈静脈静脈静脈静脈静脈静脈静脈静脈静脈静脈静脈静脈静脈静脈静脈静脈静脈静脈静脈静脈静脈静脈静脈静脈静脈静脈静脈静脈静脈静脈静脈静脈静脈

結論:

シルデナフィル・シトラートは,正常な冠動脈に血管拡張作用を示す.
シルデナフィル・シトラートと窒素を併用すると,著しく長期にわたる低血圧と冠動脈の血流の減少,特に重篤な静脈狭窄の動脈に起因する可能性があります.

さらに関連する動画

05:46

A Novel Inhalation Mask System to Deliver High Concentrations of Nitric Oxide Gas in Spontaneously Breathing Subjects

Published on: May 4, 2021

07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

関連する概念動画

01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...

01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...

01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...

01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...

01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

関連する実験動画